Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL736492 | 0.83 | CHRNA7 (0.42) | CHRNA7GRM2PIK3CD | |
| SCHEMBL3224637 | 0.80 | HTR2A (0.35) | CHRNA7GRM2PIK3CD | |
| Hydrochloric Acid SCHEMBL3222393 | 0.79 | HTR2A (0.34) | CHRNA7PIK3CD | |
| SCHEMBL11368679 | 0.78 | MEN1 (0.35) | CHRNA7PIK3CD | |
| SCHEMBL30623558 | 0.77 | GRM2 (0.31) | GRM2PIK3CD | |
| SCHEMBL30623733 | 0.74 | GRIN1 (0.30) | GRM2 | |
| SCHEMBL30623589 | 0.74 | GRM2 (0.30) | GRM2 | |
| SCHEMBL6620481 | 0.73 | AKR1B1 (0.33) | — | |
| SCHEMBL30623663 | 0.73 | GRIN1 (0.33) | — | |
| SCHEMBL30623700 | 0.73 | PIK3CD (0.38) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538122-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080139544-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-06-12 | — | — | US | disclosed |
| US-7332500-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-02-19 | — | — | US | disclosed |
| US-20050176703-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139544-A1 | Heterocyclic antiviral compounds | CCR5, CCR3, CCR1 | CHRNA7 2308/4885GRM2 655/4885PIK3CD 730/4885 |
| US-20050176703-A1 | Heterocyclic antiviral compounds | CCR5, CCR3, CCR1 | CHRNA7 2308/4885GRM2 655/4885PIK3CD 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.